Cargando…

Oral uracil–tegafur compared with intravenous chemotherapy as adjuvant therapy for resected early‐stage non‐small cell lung cancer patients

BACKGROUND: Studies comparing the effectiveness of either adjuvant oral uracil‐tegafur (UFT) or intravenous chemotherapy on early‐stage (stage I and II) non‐small cell lung cancer (NSCLC) patients treated with complete surgical treatment remain limited. METHODS: From January 2011 to December 2017, p...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Sheng‐Kai, Wu, Chang‐Wei, Chang, Ching‐I, Keng, Li‐Ta, Lee, Meng‐Rui, Wang, Jann‐Yuan, Ko, Jen‐Chung, Liao, Wei‐Yu, Chen, Kuan‐Yu, Ho, Chao‐Chi, Shih, Jin‐Yuan, Yu, Chong‐Jen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10523960/
https://www.ncbi.nlm.nih.gov/pubmed/37559409
http://dx.doi.org/10.1002/cam4.6440
_version_ 1785110652363210752
author Liang, Sheng‐Kai
Wu, Chang‐Wei
Chang, Ching‐I
Keng, Li‐Ta
Lee, Meng‐Rui
Wang, Jann‐Yuan
Ko, Jen‐Chung
Liao, Wei‐Yu
Chen, Kuan‐Yu
Ho, Chao‐Chi
Shih, Jin‐Yuan
Yu, Chong‐Jen
author_facet Liang, Sheng‐Kai
Wu, Chang‐Wei
Chang, Ching‐I
Keng, Li‐Ta
Lee, Meng‐Rui
Wang, Jann‐Yuan
Ko, Jen‐Chung
Liao, Wei‐Yu
Chen, Kuan‐Yu
Ho, Chao‐Chi
Shih, Jin‐Yuan
Yu, Chong‐Jen
author_sort Liang, Sheng‐Kai
collection PubMed
description BACKGROUND: Studies comparing the effectiveness of either adjuvant oral uracil‐tegafur (UFT) or intravenous chemotherapy on early‐stage (stage I and II) non‐small cell lung cancer (NSCLC) patients treated with complete surgical treatment remain limited. METHODS: From January 2011 to December 2017, patients with early‐stage NSCLC (defined as tumor size >3 cm without mediastinal lymph node involvement or any distant metastasis) receiving either adjuvant oral UFT or intravenous chemotherapy after surgical resection were identified from the Taiwan Cancer Registry. Overall survival (OS) and relapse‐free survival (RFS) were the primary and secondary outcomes, respectively. Propensity matching was used for controlling confounders. RESULTS: A total of 840 patients receiving adjuvant therapy after surgery (including 595 oral UFT and 245 intravenous chemotherapy) were enrolled. Before matching, patients using oral UFT had significantly longer OS (HR: 0.69, 95% CI: 0.49–0.98, p = 0.0387) and RFS (HR: 0.79, 95% CI: 0.61–0.97, p = 0.0392) than those with intravenous chemotherapy. A matched cohort of 352 patients was created using 1:1 propensity score‐matching. In the Cox regression analysis, the UFT and the matched chemotherapy groups had similar OS (HR: 0.80, 95% CI: 0.48–1.32, p = 0.3753) and RFS (HR: 0.98, 95% CI: 0.72–1.34, p = 0.9149). Among subgroup analysis, oral UFT use was associated with longer RFS among the subgroups of non‐drinker (HR: 0.66, 95% CI: 0.34–0.99, p = 0.0478) and patients with stage IB disease (HR: 0.67, 95% CI: 0.42–0.97, p = 0.0341). CONCLUSIONS: This population‐based study in the real‐world setting of Taiwan demonstrates comparable effectiveness between oral UFT and intravenous chemotherapy in terms of clinical outcomes for early‐stage NSCLC patients after surgery.
format Online
Article
Text
id pubmed-10523960
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-105239602023-09-28 Oral uracil–tegafur compared with intravenous chemotherapy as adjuvant therapy for resected early‐stage non‐small cell lung cancer patients Liang, Sheng‐Kai Wu, Chang‐Wei Chang, Ching‐I Keng, Li‐Ta Lee, Meng‐Rui Wang, Jann‐Yuan Ko, Jen‐Chung Liao, Wei‐Yu Chen, Kuan‐Yu Ho, Chao‐Chi Shih, Jin‐Yuan Yu, Chong‐Jen Cancer Med RESEARCH ARTICLES BACKGROUND: Studies comparing the effectiveness of either adjuvant oral uracil‐tegafur (UFT) or intravenous chemotherapy on early‐stage (stage I and II) non‐small cell lung cancer (NSCLC) patients treated with complete surgical treatment remain limited. METHODS: From January 2011 to December 2017, patients with early‐stage NSCLC (defined as tumor size >3 cm without mediastinal lymph node involvement or any distant metastasis) receiving either adjuvant oral UFT or intravenous chemotherapy after surgical resection were identified from the Taiwan Cancer Registry. Overall survival (OS) and relapse‐free survival (RFS) were the primary and secondary outcomes, respectively. Propensity matching was used for controlling confounders. RESULTS: A total of 840 patients receiving adjuvant therapy after surgery (including 595 oral UFT and 245 intravenous chemotherapy) were enrolled. Before matching, patients using oral UFT had significantly longer OS (HR: 0.69, 95% CI: 0.49–0.98, p = 0.0387) and RFS (HR: 0.79, 95% CI: 0.61–0.97, p = 0.0392) than those with intravenous chemotherapy. A matched cohort of 352 patients was created using 1:1 propensity score‐matching. In the Cox regression analysis, the UFT and the matched chemotherapy groups had similar OS (HR: 0.80, 95% CI: 0.48–1.32, p = 0.3753) and RFS (HR: 0.98, 95% CI: 0.72–1.34, p = 0.9149). Among subgroup analysis, oral UFT use was associated with longer RFS among the subgroups of non‐drinker (HR: 0.66, 95% CI: 0.34–0.99, p = 0.0478) and patients with stage IB disease (HR: 0.67, 95% CI: 0.42–0.97, p = 0.0341). CONCLUSIONS: This population‐based study in the real‐world setting of Taiwan demonstrates comparable effectiveness between oral UFT and intravenous chemotherapy in terms of clinical outcomes for early‐stage NSCLC patients after surgery. John Wiley and Sons Inc. 2023-08-09 /pmc/articles/PMC10523960/ /pubmed/37559409 http://dx.doi.org/10.1002/cam4.6440 Text en © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle RESEARCH ARTICLES
Liang, Sheng‐Kai
Wu, Chang‐Wei
Chang, Ching‐I
Keng, Li‐Ta
Lee, Meng‐Rui
Wang, Jann‐Yuan
Ko, Jen‐Chung
Liao, Wei‐Yu
Chen, Kuan‐Yu
Ho, Chao‐Chi
Shih, Jin‐Yuan
Yu, Chong‐Jen
Oral uracil–tegafur compared with intravenous chemotherapy as adjuvant therapy for resected early‐stage non‐small cell lung cancer patients
title Oral uracil–tegafur compared with intravenous chemotherapy as adjuvant therapy for resected early‐stage non‐small cell lung cancer patients
title_full Oral uracil–tegafur compared with intravenous chemotherapy as adjuvant therapy for resected early‐stage non‐small cell lung cancer patients
title_fullStr Oral uracil–tegafur compared with intravenous chemotherapy as adjuvant therapy for resected early‐stage non‐small cell lung cancer patients
title_full_unstemmed Oral uracil–tegafur compared with intravenous chemotherapy as adjuvant therapy for resected early‐stage non‐small cell lung cancer patients
title_short Oral uracil–tegafur compared with intravenous chemotherapy as adjuvant therapy for resected early‐stage non‐small cell lung cancer patients
title_sort oral uracil–tegafur compared with intravenous chemotherapy as adjuvant therapy for resected early‐stage non‐small cell lung cancer patients
topic RESEARCH ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10523960/
https://www.ncbi.nlm.nih.gov/pubmed/37559409
http://dx.doi.org/10.1002/cam4.6440
work_keys_str_mv AT liangshengkai oraluraciltegafurcomparedwithintravenouschemotherapyasadjuvanttherapyforresectedearlystagenonsmallcelllungcancerpatients
AT wuchangwei oraluraciltegafurcomparedwithintravenouschemotherapyasadjuvanttherapyforresectedearlystagenonsmallcelllungcancerpatients
AT changchingi oraluraciltegafurcomparedwithintravenouschemotherapyasadjuvanttherapyforresectedearlystagenonsmallcelllungcancerpatients
AT kenglita oraluraciltegafurcomparedwithintravenouschemotherapyasadjuvanttherapyforresectedearlystagenonsmallcelllungcancerpatients
AT leemengrui oraluraciltegafurcomparedwithintravenouschemotherapyasadjuvanttherapyforresectedearlystagenonsmallcelllungcancerpatients
AT wangjannyuan oraluraciltegafurcomparedwithintravenouschemotherapyasadjuvanttherapyforresectedearlystagenonsmallcelllungcancerpatients
AT kojenchung oraluraciltegafurcomparedwithintravenouschemotherapyasadjuvanttherapyforresectedearlystagenonsmallcelllungcancerpatients
AT liaoweiyu oraluraciltegafurcomparedwithintravenouschemotherapyasadjuvanttherapyforresectedearlystagenonsmallcelllungcancerpatients
AT chenkuanyu oraluraciltegafurcomparedwithintravenouschemotherapyasadjuvanttherapyforresectedearlystagenonsmallcelllungcancerpatients
AT hochaochi oraluraciltegafurcomparedwithintravenouschemotherapyasadjuvanttherapyforresectedearlystagenonsmallcelllungcancerpatients
AT shihjinyuan oraluraciltegafurcomparedwithintravenouschemotherapyasadjuvanttherapyforresectedearlystagenonsmallcelllungcancerpatients
AT yuchongjen oraluraciltegafurcomparedwithintravenouschemotherapyasadjuvanttherapyforresectedearlystagenonsmallcelllungcancerpatients